Pfizer has announced the decision to discontinue development of Danuglipron ( PF-06882961 ), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.

Dose-optimization studies of once-daily formulations of Danuglipron met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in phase 3 testing, based on earlier studies of twice-daily Danuglipron.

While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of Danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of Danuglipron.

After a review of the totality of information, including all clinical data generated for Danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule. ( Xagena_2025 )

Source: Pfizer, 2025

XagenaMedicine_2025